News

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...
Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the ...
Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.
Results for the second quarter were a bit better than expected. Non-GAAP earnings were $2.13 per share, better than the $2.02 ...
Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...
As Merck gears up for its Q2 earnings, all eyes are on Keytruda, its oncology superstar. Keytruda, accounting for nearly half of Merck’s pharma sales, is anticipated to report Q2 sales of $7.90 ...
As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline growth drivers.